Markman Advisors
Patent Valuation, Monetization and Investments


Markman Advisors Patent Blog

Posts tagged CAR-T
Can Kite Pharma reverse its IPR loss challenging Juno’s CAR-T patent?

On June 5, 2018, the Federal Circuit will hear oral argument on Kite Pharma’s ($GILD) appeal of its IPR loss related to Sloan-Kettering’s and Juno Therapeutic’s ($CELG) CAR-T patent.  What issues will it be important to listen for in the panel’s questions?

Read More